After UnitedHealthcare CEO Brian Thompson was shot to death in December, law enforcement records show a burst of police ...

The company says preclinical trials demonstrate its signature molecule can help prevent cell damage that can lead to ...

The U.S. faces a potential 'Quad-emic' with rising cases of flu, COVID, RSV, and norovirus. Older adults, especially those ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Agreement,: Moderna will supply its mRNA COVID-19 vaccine to 17 participating countries in the EU, Norway, and North ...

Tesla Inc. faces diverging forecasts for its 2025 delivery growth, with Wall Street's expectations clashing with independent ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...